Human Epidermal Growth Factor Receptor 2-Subtype Invasive Ductal Carcinoma Recurring as Basal-Human Epidermal Growth Factor Receptor 2-Subtype Squamous Cell Carcinoma

Jeongshin An 1, Youngeun Yoo 2, Hyun Goo Kim 1, Joohyun Woo 1, Kyoun Eun Lee 2, Hyungju Kwon 1, Woosung Lim 1, Sun Hee Sung 2, Nam Sun Paik 1, Byung-In Moon 1

1 Department of Surgery, Ewha Woman’s University School of Medicine, Seoul, Korea
2 Department of Pathology, Ewha Woman’s University School of Medicine, Seoul, Korea
3 Department of Hematology-Oncology, Ewha Woman’s University School of Medicine, Seoul, Korea

ABSTRACT

Squamous cell carcinoma of the breast and its subtype, basal-human epidermal growth factor receptor 2 (HER2) phenotype, are very rare. Herein, we report a patient who developed recurrence of squamous cell carcinoma of the breast with basal-HER2 subtype 6 years after the initial diagnosis of invasive ductal carcinoma of the HER2 subtype. To the best of our knowledge, recurrence of invasive ductal carcinoma in the form of metaplastic squamous cell carcinoma of basal-HER2 subtype has not been reported previously. We present a pathological perspective of our experience.

Keywords: Breast; Ductal carcinoma; Pathology; Squamous cell carcinoma

INTRODUCTION

Invasive ductal carcinoma accounts for approximately 70%-80% of all invasive breast cancers. Squamous cell carcinoma of the breast is a very rare type, accounting for approximately 0.1% of breast cancer cases [1]. Herein, we present a case of invasive ductal carcinoma that recurred as squamous cell carcinoma of the breast. The patient had previously been diagnosed with the human epidermal growth factor receptor 2 (HER2) subtype of invasive ductal carcinoma, which relapsed as basal-HER2-subtype squamous cell carcinoma after 6 years. Squamous cell carcinoma of the breast tends to grow rapidly and is resistant to chemotherapy [2]. It is also associated with frequent development of cystic lesions [3], showing aggressive progression compared with that in other types of breast cancer [4]. Metaplastic breast cancer is related to the basal-like subtype [5]; among these, the basal-HER2 subtype is particularly rare. This report describes a case of relapsed basal-HER2 subtype of metaplastic squamous cell carcinoma of the breast.
CASE REPORT

A 49-year-old female patient presented with left periductal mastitis with nipple retraction in April 2018. Her chief complaint was left breast swelling with a febrile sensation. The patient had a previous history of invasive ductal carcinoma of the left breast in May 2012, which was managed with breast-conserving surgery and sentinel lymph node biopsy. The breast carcinoma was estrogen (prediluted, SP1; Ventana Medical Systems, Inc., Tucson, USA) and progesterone (prediluted, 1E2; Ventana Medical Systems, Inc.) receptor-negative, and the HER2 (prediluted, 4B5; Ventana Medical Systems, Inc.) score was 3+. The histopathologic result in the first surgery indicated HER2-subtype invasive ductal carcinoma. The tumor cells invaded the stroma in the form of linear strands or cords of various sizes. The nuclei of the neoplastic cells moderately varied in size; they had limited tubule formation capacity and a moderate mitotic count. HER2 immunohistochemistry showed 3+ immunoreactivity within the circumferential membrane of the tumor cells (Figure 1A and B). The basal markers cytokeratin (CK) 5/6 and epidermal growth factor receptor (EGFR) tested negative. Following the diagnosis of the relapsed mass in 2018, the basal markers that were investigated in the recurrent mass were re-examined in the first surgical specimen. Even after repeated immunostaining for CK 5/6 (1:100; B5/16 B4; DAKO, Kyoto, Japan) and EGFR (1:50; SP84; Cell Marque, Rocklin, USA), negative results were obtained (Figure 1C and D). The tumor–node–metastasis stage was stage IIA, T1cN1M0. After the first surgery, she received 4 cycles of doxorubicin and cyclophosphamide treatment, followed by 4 cycles of docetaxel. After 6 months of chemotherapy, radiation therapy was also completed, and 18 cycles of trastuzumab treatment were administered for 1 year. Thereafter, she was regularly followed up for the next

Figure 1. Microscopic findings of the surgical specimen in May 2012. (A) High-grade invasive ductal carcinoma during the first surgery in May 2012 (×200, hematoxylin and eosin stain). (B) Human epidermal growth factor receptor 2 positivity of the invasive ductal carcinoma during the first surgery in May 2012 (×200, immunohistochemistry). (C) Cytokeratin 5/6 was not expressed in all tumor cells of the invasive ductal carcinoma. (D) Epidermal growth factor receptor was also not expressed in the invasive ductal carcinoma.
4 years. However, she skipped the scheduled examination in November 2017. After that, she visited the clinic with left periductal mastitis in April 2018. Breast ultrasound was performed, revealing a complex solid and cystic mass (approximately 3.5 × 1.9 cm) in the left upper central breast. The skin overlying her left breast showed diffuse thickening (Figure 2A and B). The cystic lesion was aspirated, and the aspiration fluid was turbid and yellowish. The aspiration fluid was cultured, and no bacteria were found. She was treated on the basis of suspected mastitis due to the abscess in the left breast. In May 2018, the abscess was incised, drained, and cultured again; however, no cultured bacteria were found (Figure 2C). After the initial incision and drainage, the tumor had enlarged. The size of the complex mass increased to approximately 5.5 × 3.8 cm (Figure 2D and E). A core-needle biopsy of the left breast lesion revealed squamous cell carcinoma. She opted to undergo left breast mastectomy, and as a preoperative evaluation, breast magnetic resonance imaging was performed, which showed a left breast mass abutting the pectoralis muscle with enlarged right axillary lymph nodes (Figure 3A). Positron emission tomography-computed tomography was performed to evaluate other metastatic lesions. Except for that in the right axillary lymph nodes, metastasis was not detected. In July 2018, her second surgery was performed because of relapsed left breast cancer. She underwent a left simple mastectomy and right axillary lymph node biopsy (Figure 3B and C). The histopathological result of the second surgery was metaplastic squamous cell carcinoma of basal-HER2 subtype. The course of treatment was
decided by a multidisciplinary team, with inputs from various experts in the departments of surgery, oncology, pathology, and radiology. Her invasive ductal carcinoma had been locally controlled since 2012. Therefore, the best course of action was decided to be the repeated anthracycline and taxane chemotherapy, followed by trastuzumab, postmastectomy radiation therapy, tamoxifen, and goserelin.

The tumor was completely resected after the surgical treatment. Left axillary lymph node dissection was not performed because no enlarged or suspected malignant lymph nodes were detected during the second surgery. A frozen biopsy of the right axillary lymph nodes yielded negative results for malignancy. Therefore, right axillary lymph node dissection was not performed. No recurrence was observed, and chemotherapy is currently ongoing.

The relapsed cancer in 2018 was pure squamous cell carcinoma and showed positive results for the breast cancer marker GATA binding protein 3. This recurring mass consisted of large polygonal malignant cells containing intercellular bridges and abundant eosinophilic cytoplasm with nuclear atypia and focal pycnotic keratinization found in squamous cell carcinoma (Figure 4A). The immunophenotype of this recurred mass was determined to be the basal-HER2 subtype. The Allred scores for estrogen and progesterone receptors were 2 and 6, respectively, and the HER2 score was 3+. The recurrent tumor cells showed strong expression of CK 5/6 in their cytoplasm and cell membrane and diffuse moderate membranous staining of EGFR (Figure 4B-D).
DISCUSSION

We encountered a case of HER2-subtype invasive ductal carcinoma that recurred as basal-HER2-subtype squamous cell carcinoma of the breast. The tumor cells in the specimen from the first surgery did not show any expression of basal markers despite repeated staining. Phenotypes of invasive ductal carcinoma are not commonly completely changed to squamous cell carcinoma of the breast, especially the basal-HER2 subtype. Squamous cell carcinoma of the breast is a type of metaplastic carcinoma. Most metaplastic breast cancers (approximately 95%) are basal-like subtypes, according to previous microarray data [5]. Overexpression of the HER2/neu gene was reported in only 6% of cases of squamous cell carcinoma of the breast [6], which included both pure HER2 and basal-HER2 subtypes. According to a case report published in 2014, 3 cases of basal-HER2-subtype squamous cell carcinoma of the breast were reported among all 25,232 cases of invasive breast cancer during a 5-year period [7]. These were not cases of relapsed breast cancer, but were primary cases. According to another case report, invasive ductal carcinoma of the triple-negative subtype and adenocarcinoma recurred in a patient as squamous cell carcinoma of the breast [8]. Most previously published papers are about primary squamous cell carcinoma of the breast, apart from these aforementioned case reports. No recurrence data of basal-HER2-subtype breast cancer exist. Herein, we report a case of squamous cell carcinoma of the breast of basal-HER2 subtype at the previous site of invasive ductal carcinoma.
Both the basal-HER2 molecular subtype and squamous cell carcinoma of histopathologic subtype of the breast are characterized by poor prognosis. The basal-HER2 subtype is found in 9% of HER2-overexpressing tumors in invasive cancer [9]. The basal-HER2 subtype is characterized by poorly differentiated invasive ductal cancers or squamous cell carcinoma of the breast with a high level of p53 expression [10]. The basal-HER2 subtype confers poor disease-free survival compared to that conferred by other subtypes [11]. The 5-year overall survival rate of patients harboring the basal-HER2 subtype is reported to be 65%, whereas that of patients harboring the HER2 subtype is 96% [9]. The 5-year overall survival rate for the histopathologic subtype of squamous cell carcinoma of the breast has been shown to be 67.2% in previous studies [4]. However, no large-scale data showed the 5-year survival in those with basal-HER2-subtype squamous cell carcinoma of the breast, given its rarity. Its poor prognosis may also be partly because of its clinical resemblance to mastitis. Indeed, this case mimicked an inflammatory condition. Pure squamous cell carcinoma of the breast frequently results in large cystic changes with a necrotic background [3]. Therefore, malignancy is overlooked because of an abscess or pus-like lesion, leading to delayed diagnosis. Squamous cell carcinoma of the breast is also characterized by rapid growth. In the present case, the tumor rapidly grew enough to be visible within the 2-month period. For complex masses including both solid and cystic parts, as that in this case, the status of malignancy should be confirmed via core needle biopsy.

In this case, the nature of the breast tumor had changed despite the recurrence of cancer at the same site. Changes in the nature of the recurring tumor may be due to 2 reasons: radiation therapy that changes the microenvironment, including the surrounding immune cells of the tumor [12], and chemotherapies that also help modify the tumor characteristics into something different from the original tumor characteristics [13]. Breast cancer comprises a group of heterogeneous cells that are sensitive to treatment, which are dead and replaced by cells that are resistant to treatment. This process changes the tumor characteristics that adapt to the treatment and exhibit resistance to therapy. In this case, since the cancer recurred after chemotherapy and radiation therapy, only the cancer cells resistant to the previous treatment survived, resulting in new cellular characteristics.

In conclusion, HER2-subtype invasive ductal carcinoma can recur as basal-HER2-subtype squamous cell carcinoma of the breast with poor prognosis. The nature of the tumor in this case may have been changed due to the patient’s treatment history. The possibility of cancer recurrence should be considered for cystic lesions occurring at the site of a previous breast cancer lesion.

REFERENCES

1. Cardoso F, Leal C, Meira A, Azevedo R, Mauricio MJ, Leal da Silva JM, et al. Squamous cell carcinoma of the breast. Breast 2000;9:315-9. [PUBMED] [CROSSREF]
2. Aparicio I, Martínez A, Hernández G, Hardisson D, De Santiago J. Squamous cell carcinoma of the breast. Eur J Obstet Gynecol Reprod Biol 2008;137:222-6. [PUBMED] [CROSSREF]
3. Siegelmann-Danieli N, Murphy TJ, Meschter SC, Stein ME, Prichard J. Primary pure squamous cell carcinoma of the breast. Clin Breast Cancer 2005;6:270-2. [PUBMED] [CROSSREF]
4. Zhang X, Zhang B, Zang F, Zhao L, Yuan Z, Wang P. Clinical features and treatment of squamous cell carcinoma of the breast. Onco Targets Ther 2016;9:3181-5.

5. Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat 2009;117:273-80.

6. Hennessy BT, Krishnamurthy S, Giordano S, Buchholz TA, Kau SW, Duan Z, et al. Squamous cell carcinoma of the breast. J Clin Oncol 2005;23:7827-35.

7. Shui R, Li A, Yang F, Zhou X, Yu B, Xu X, et al. Primary squamous cell carcinoma of the breast with unusual basal-HER2 phenotype. Int J Clin Exp Pathol 2014;7:5203-9.

8. Singh H, Williams SP, Kinsella V, Lynch GR. Postradiation squamous cell cancer of the breast. Cancer Invest 2000;18:343-6.

9. Bagaria SP, Ray PS, Wang J, Kropcho L, Chung A, Sim MS, et al. Prognostic value of basal phenotype in HER2-overexpressing breast cancer. Ann Surg Oncol 2012;19:935-40.

10. Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Hum Pathol 2008;39:167-74.

11. Sagara Y, Takada M, Ohi Y, Ohtani S, Kurozumi S, Inoue K, et al. Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03. Breast Cancer Res Treat 2018;171:675-83.

12. Filatenkov A, Baker J, Mueller AM, Kenkel J, Ahn GO, Dutt S, et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res 2015;21:3727-39.

13. Keener AB. Shapeshifters in cancer: how some tumor cells change phenotype to evade therapy. Nat Med 2016;22:1194-6.